- Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs
- CAR-T is a type of cellular therapy that reprograms the immune cells of cancer patients to recognise and destroy cancerous cells
- PTX has an existing research agreement with Peter Mac focusing on cell therapy enhancement programs, which also looks to improve the current CAR-T approaches
- This new agreement extends the relationship between the parties to include the development of the OmniCAR platform
- Under the terms of the research agreement, PTX will also have access to the expertise and facilities of Peter Mac
- On the market today, PTX is up 1.12 per cent, trading at 9 cents per share
